Investor Presentaiton
Mirati Therapeutics: Strong Strategic Fit
Extending in 10
OPDIVO
(nivolumab)
Opdualag
Best-in-class KRASG12C inhibitor approved in 2L+ mutated NSCLC;
confirmatory Ph3 results expected 1H 2024
• Potential KRASG12C mutated tumor opportunities: 1L NSCLC; 2L & 3L+ CRC
Development
Status
Ph3 initiation by YE 2023
Indication
TPS ≥50%: Krazati + pembrolizumab
1L NSCLC
YERVOY
TPS <50%: Krazati + pembrolizumab + chemo
Ph2 data expected in 1H 2024
(ipilimumab)
Injection for intravenous use | 480 mg/160 mg
2L CRC
Krazati + cetuximab
3L+ CRC
Ph3 data expected in 2024
Ph2 submission expected by YE 2023
(nivolumab and relatlimab-rmbw)
Diversifying beyond 10
repotrectinib¹
(U.S. PDUFA: 11/27/23)
KRAZATI®
(adagrasib)
200 mg
TABLETS
2
Selective PRMT5/MTA inhibitor (MRTX1719): Potential first-in-class asset
Ph2 expected to initiate 1H 2024; Fast Track Designation granted
Early Clinical Programs: Additional opportunities from KRAS inhibitors &
enabling programs (e.g., SOS1 inhibitor)
Planned close by 1H 20242
ll Bristol Myers Squibb Q3 2023 Results
1. Acquired from Turning Point Therapeutics
Not for Product Promotional Use
9
2. Subject to satisfaction of customary closing conditions; anticipated closing by 1H 2024View entire presentation